POLICIES AND PROCEDURE
MANUAL

Policy: MP248
Section: Medical Benefit Policy
Subject: Single Nucleotide Polymorphisms (SNPs) to Predict Risk of Non-Familial Breast Cancer

I. Policy: Single Nucleotide Polymorphisms (SNPs) to Predict Risk of Non-Familial Breast Cancer

II. Purpose/Objective:
   To provide a policy of coverage regarding Single Nucleotide Polymorphisms (SNPs) to Predict Risk of Non-Familial Breast Cancer

III. Responsibility:
   A. Medical Directors
   B. Medical Management

IV. Required Definitions
   1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
   2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
   3. Devised – the date the policy was implemented.
   4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
   5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
   Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

   a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
   b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
   c. in accordance with current standards of good medical treatment practiced by the general medical community.
   d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
   e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
   Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

   (i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
   (ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
   (iii) The service or benefit will assist the Member to achieve or maintain maximum functional
capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

DESCRIPTION:
Single nucleotide polymorphisms, usually referred to as SNPs, are small genetic changes among single base nucleotides. Researchers suggest that SNPs in functional regions of genes involved in sex hormone synthesis, signaling and metabolism may differentially impact breast cancer risk, depending on the person’s age or menopausal status. The available assays are designed to test for several SNPs, which are thought to predict an individual's risk of breast cancer relative to the general population in order to identify those at increased risk who might benefit from more intensive surveillance. There are several SNP tests available which include but is not limited to BREVAGen, OncoVue, deCODEBrestCancer, 23andMe, and Navigenics.

EXCLUSIONS:
The Plan does NOT provide coverage for the testing for one or more single nucleotide polymorphisms (SNPs) to predict an individual's risk of breast cancer because it is considered experimental, investigational or unproven. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this test on health outcomes when compared to established tests or technologies.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Single Nucleotide Polymorphisms (SNPs) to Predict Risk of Non-Familial Breast Cancer
The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

81479 Unlisted molecular pathology procedure
81599 Unlisted multianalyte assay with algorithmic analysis


LINE OF BUSINESS:
Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD's will supersede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:


This policy will be revised as necessary and reviewed no less than annually.

Devised: 1/17/11

Revised:

Reviewed: 2/12, 2/13, 2/14, 2/15, 2/16, 2/17, 1/18, 1/19